All In Biotech

Drug Trial Radar · NCT06926998

9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

An Open-Label, Multicenter Phase Ib/ll Clinical Study Evaluating the Safety and Efficacy of 9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors

Last checked: Nov 20, 2026Latest source record: Apr 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Apr 15, 2025

Primary completion

May 1, 2027

Study completion May 1, 2027

Sponsor

Sponsor type
Industry
First posted
Apr 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.

Conditions

  • Gynecological Malignancies

Interventions

  • 9MW2821+other anticancer therapyDrug

    Subjects will receive intravenous (IV) infusion of 9MW2821 +other anticancer therapy as per protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.